Latest News

STAT Plus: Europe approves first gene therapy to treat rare blood disease

A one-time gene therapy from Bluebird Bio won approval in Europe on Monday, marking a major milestone and giving the company a chance to learn from the field’s commercial mistakes of the past.

Bluebird’s therapy, called Zynteglo, is now cleared to treat people with beta thalassemia, a rare, inherited disease that causes the production of impaired red blood cells and severe anemia. The treatment promises to fix the genetic cause of beta thalassemia and relieve patients from the blood transfusions they would otherwise need.

Continue to STAT Plus to read the full story…

Source link




Related posts

Docs: Testosterone Supplements Won't Help Most Men

Newsemia

Gene variations linked to higher risk of diabetes and heart attacks

Newsemia

Study: Shift Work Is Tough on Workers' Hearts

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy